5th Annual Meeting of the Society for Translational Oncology

Perspectives on Progress:
Using Genomics to Guide Clinical Therapy

Friday-Saturday, April 10-11, 2015
Ohio State’s Biomedical Research Tower
Columbus, Ohio

Hosted by The James
**STO ANNUAL MEETING AGENDA**

**Friday, April 10, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:15AM</td>
<td>Welcome and Introduction</td>
<td>Martin J. Murphy, DMedSc, PhD, Convener, Society for Translational Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Richard M. Goldberg, MD, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)</td>
</tr>
<tr>
<td>8:15-9:00AM</td>
<td>Keynote Lecture: Lessons from The Cancer Genome Atlas (TCGA)</td>
<td>D. Neil Hayes, MD, MPH, UNC Lineberger Comprehensive Cancer Center</td>
</tr>
<tr>
<td>9:00-9:45AM</td>
<td>Breast and Ovarian Cancers</td>
<td>Gabriel N. Hortobágyi, MD, University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>9:45-10:15AM</td>
<td>Prognostic and Predictive Tools in Breast Cancer: Clinical and Genomic</td>
<td>Gabriel N. Hortobágyi, MD, The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>10:15-10:30AM</td>
<td>Beverage Break</td>
<td></td>
</tr>
<tr>
<td>10:30-11:00AM</td>
<td>Hematologic Malignancies</td>
<td></td>
</tr>
<tr>
<td>11:00-11:30AM</td>
<td>Biologic Heterogeneity of Acute Myeloid Leukemia (AML): Implications for Prognosis and Treatment</td>
<td>Clara D. Bloomfield, MD, OSUCCC – James</td>
</tr>
<tr>
<td>11:30-12:00PM</td>
<td>Functionally and Proteomics of Ovarian Cancer Elucidates Novel Targets and Therapies</td>
<td>Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>12:00-1:15PM</td>
<td>Lunch Buffet</td>
<td></td>
</tr>
<tr>
<td>1:15-1:45PM</td>
<td>Gastrointestinal Cancer</td>
<td></td>
</tr>
<tr>
<td>1:45-2:15PM</td>
<td>The Expanding Scope of Early Gastrointestinal Tract Cancer Diagnosis: Process and Successes of a Methyloomics Approach</td>
<td>John B. Kisiel, MD, Mayo Clinic</td>
</tr>
<tr>
<td>2:15-2:45PM</td>
<td>Using Genomics to Drive Clinical Therapy - GIST</td>
<td>Suzanne George, MD, Dana-Farber Cancer Institute, Harvard Medical School</td>
</tr>
<tr>
<td>2:45-3:00PM</td>
<td>Drink Break</td>
<td></td>
</tr>
<tr>
<td>3:00-3:30PM</td>
<td>Lung Cancer</td>
<td></td>
</tr>
<tr>
<td>3:30-4:00PM</td>
<td>Implications of Genomic Diversity in Different Lung Cancers</td>
<td>Bruce E. Johnson, MD, Dana-Farber Cancer Institute, Harvard Medical School</td>
</tr>
<tr>
<td>4:00-4:30PM</td>
<td>Tumor Heterogeneity and Clonal Evolution in Lung Cancer</td>
<td>David P. Carbone, MD, PhD, OSUCCC – James</td>
</tr>
<tr>
<td>4:30-5:00PM</td>
<td>GU Cancers</td>
<td></td>
</tr>
<tr>
<td>5:00PM</td>
<td>Adjourn Day 1</td>
<td></td>
</tr>
</tbody>
</table>
**Saturday, April 11, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50-8:00AM</td>
<td>Welcome and Introduction</td>
<td></td>
</tr>
<tr>
<td>8:00-8:15AM</td>
<td>Presentation of the 2015 Pinedo Cancer Care Prize</td>
<td>Martin J. Murphy, DMedSc, PhD, Convener, Society for Translational Oncology</td>
</tr>
</tbody>
</table>

**Pinedo Prize Awardee Lecture**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15-9:00AM</td>
<td>Integrating Pathologic and Genomic Factors to Make Treatment Decisions in Patients with GI Cancers</td>
<td>Richard M. Goldberg, MD, OSUCCC – James</td>
</tr>
</tbody>
</table>

**Geriatrics**

*Moderator: Gabriel N. Hortobágyi, MD, The University of Texas MD Anderson Cancer Center*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-9:30AM</td>
<td>Molecular Markers of Aging: Roles, Challenges, and Opportunities</td>
<td>Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center</td>
</tr>
</tbody>
</table>

**Melanoma**

*Moderator: Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30-10:00AM</td>
<td>The Genome in Treatment Selection for Metastatic Melanoma</td>
<td>Lawrence E. Flaherty, MD, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine</td>
</tr>
</tbody>
</table>

**Brain**

*Moderator: Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-9:30AM</td>
<td>Emerging Molecular Markers and Heterogeneity in Gliomas: What are the implications for patient care and treatment selection?</td>
<td>Vinay K. Puduvalli, MD, OSUCCC – James</td>
</tr>
</tbody>
</table>

10:15-10:30AM    | Beverage Break                                                       |                                                                                 |

**Precision Tumor Board**

*Moderator: Richard M. Goldberg, MD, OSUCCC – James*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45-11:15AM</td>
<td>Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine</td>
<td>Sameek Roychowdhury, MD, PhD, OSUCCC – James</td>
</tr>
</tbody>
</table>

**The Potential of Total Cancer Care (TCC)**

*Moderator: Richard M. Goldberg, MD, OSUCCC – James*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15-11:45AM</td>
<td>The Oncology Research Information Exchange Network (ORIEN)</td>
<td>Michael A. Caligiuri, MD, OSUCCC – James</td>
</tr>
</tbody>
</table>

**Radiology and Genomic Imaging**

*Moderator: Richard M. Goldberg, MD, OSUCCC – James*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-12:15PM</td>
<td>Radiology and Genomic Imaging</td>
<td>Michael V. Knopp, MD, OSUCCC – James</td>
</tr>
<tr>
<td>12:15PM</td>
<td>Closing Remarks and Adjourn Day 2 Boxed Lunch Available</td>
<td></td>
</tr>
</tbody>
</table>

---

The content of each presentation does not necessarily reflect the views of the Society for Translational Oncology, *The Oncologist*, or OSUCCC – James or any of its affiliates.

Slides will not be printed for the meeting in an effort to protect the environment. Any requests for slides should be directed to the specific presenter as STO does not have permission to distribute slides on their behalf.
Overview
For the fifth year, this symposium of notable speakers, representing both research and clinical practice, will convene before a fully engaged audience, providing a unique opportunity for education, interaction and collaboration.

Cancer treatment has progressed within the last decade. Researchers have a better understanding of cancer biology and viral oncology; clinical studies have identified potential cancer biomarkers, and researchers are investigating how genetic variations could be used to stratify patients for risk as well as treatment. The development of targeted therapies is advancing the practice of individualized medicine.

Ongoing professional education is an essential component of improving patient care and outcomes in the oncology setting, where advances occur rapidly. Professional education activities help clinicians to identify best practice models, develop new clinical skills, and put current knowledge into action.

To this end, STO endeavors to conduct this meeting to achieve the following overall goals based on identification of current and best practices:

• Bringing knowledge and strategies for critical new developments in cancer treatment into the practice environment of the community oncologist.
• Bridging the “translational gap” between discovery and delivery of care to the patient.
• Providing educational activities to improve physician competencies and strategies for screening, prevention, diagnosis, treatment, and management of patients with cancer.

Target Audience
This activity will be designed to meet the educational needs of physicians, scientists and other healthcare professionals in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

Accreditation
The Society for Translational Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The Society for Translational Oncology designates this live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credit
In order to receive CME credit, learners must sign in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.), and attend the CME activity. Learners will be asked to complete an electronic activity evaluation following the meeting and indicate the number of credit hours claimed. Certificates will be provided upon completion of the evaluation.

To obtain CME credit, please visit: http://bit.ly/STOSMtGCMECredit.

ACKNOWLEDGEMENTS

STO gratefully acknowledges educational grants in partial support of this activity from:

- Amgen
- AstraZeneca
- BioMarin Pharmaceutical Inc.
- Celgene Corporation
- Genentech
- Genomic Health, Inc.
- Incyte Corporation
- Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC
- Novartis Pharmaceuticals Corporation
- Pfizer
- Taiho Oncology, Inc.
- Takeda Oncology

STO also gratefully acknowledges our exhibitors:

- Pfizer
- Genoptix Medical Laboratory
**FINANCIAL DISCLOSURES**

In accordance with ACCME Standards for Commercial Support and the policies of the Society for Translational Oncology (STO), persons participating in this activity who are in a position to control the content have disclosed all relevant relationships with any commercial interest. On the basis of disclosed information, STO identifies and resolves all conflicts of interest before delivery of content.

**STO staff involved in the development of this activity have nothing to disclose.**

The following faculty have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.

<table>
<thead>
<tr>
<th>Name</th>
<th>Financial Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clara D. Bloomfield, MD</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>John C. Byrd, MD</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Michael A. Caligiuri, MD</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>David P. Carbone, MD, PhD</td>
<td>Consultant/advisory role: Bayer Health Care, Biothera, Boehinger Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, GlaxoSmithKline, MedImmune, Merck, Novartis, Pfizer, Synta Pharmaceuticals Corp.</td>
</tr>
<tr>
<td>Bruce A. Chabner, MD</td>
<td>Consultant/advisory role: Merrimack Pharmaceuticals, Sanofi, Epizyme, PharmaMar</td>
</tr>
<tr>
<td>Lawrence E. Flaherty, MD</td>
<td>Consultant/advisory role: Roche Genentech (advisory), Merck (Data Safety Monitor Committee)</td>
</tr>
<tr>
<td>Suzanne George, MD</td>
<td>Consultant/advisory role: Blueprint Medicines, Ariad</td>
</tr>
<tr>
<td>Richard M. Goldberg, MD</td>
<td>Consultant/advisory role: Sanofi, Biothera, Lilly, Novartis, Baxter, Bayer, Kanghong, Taiho</td>
</tr>
<tr>
<td>D. Neil Hayes, MD, MPH</td>
<td>Employment/leadership position: GeneCentric Diagnostics</td>
</tr>
<tr>
<td>Craig C. Hofmeister, MD, MPH</td>
<td>Consultant/advisory role: Antigen Express, Bayer, Metastat, Novartis, Peregrine, Pfizer</td>
</tr>
<tr>
<td>Bruce E. Johnson, MD</td>
<td>Property rights/patents: EGFR mutation testing (Post-marketing royalties)</td>
</tr>
<tr>
<td>William Y. Kim, MD</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>John B. Kisiel, MD</td>
<td>Consultant/advisory role: AstraZeneca, Blend Therapeutics, Critical Outcome Technologies, HanAl Bio Korea, Illumina, Nuevolution, Pfizer, Provista Diagnostics, Roche, SignalChem Lifesciences, Symphogen, Cavion</td>
</tr>
<tr>
<td>Michael V. Knopp, MD, PhD</td>
<td>Consultant/advisory role: Exact Sciences Corporation</td>
</tr>
<tr>
<td>Gordon B. Mills, MD, PhD</td>
<td>Consultant/advisory role: AstraZeneca, Blend Therapeutics, Critical Outcome Technologies, HanAl Bio Korea, Illumina, Nuevolution, Pfizer, Provista Diagnostics, Roche, SignalChem Lifesciences, Symphogen, Cavion</td>
</tr>
<tr>
<td>Hyman B. Muss, MD</td>
<td>Consultant/advisory role: Eisai, Pfizer</td>
</tr>
<tr>
<td>Peter J. O’Dwyer, MD</td>
<td>Consultant/advisory role: Genentech, Five Prime</td>
</tr>
<tr>
<td>Vinay K. Puduvalli, MD</td>
<td>Consultant/advisory role: Celgene, Foundation Medicine</td>
</tr>
<tr>
<td>Sameek Roychowdhury, MD, PhD</td>
<td>Consultant/advisory role: Celgene, Foundation Medicine</td>
</tr>
</tbody>
</table>

**Expert testimony:**

- Eli Lilly
- Genentech
- Catena Pharmaceuticals, PTV Ventures, Spindle Top Ventures
- Johnson & Johnson

**Research funding:**

- Roche, BMS, Pfizer, Merck, GSK, AstraZeneca
- Novartis, Pfizer, Ariad, Bayer
- Abbott Labs, AbbVie
- Bayer, Sanofi

**Ownership Interest:**

- Catena Pharmaceuticals, PTV Ventures, Spindle Top Ventures
- Johnson & Johnson

**Consultant/advisory role:**

- Oncology Meeting Innovations, Puma Biotechnology, Inc., Novartis, Merck and Company, AstraZeneca, KEW Group, LLC, Transgene, Otsuka Pharmaceutical Company, Bristol-Myers Squibb, Clovis Oncology, Chugai
- KEW Group, LLC

**Honoraria:**

- AstraZeneca, Blend, Critical Outcome Technologies, HanAl Bio Korea, Illumina, Nuevolution, Pfizer, Provista Diagnostics, Roche, SignalChem Lifesciences, Symphogen, Cavion

**Research funding:**

- Adelson Medical Research Foundation, AstraZeneca, Critical Outcomes Technologies, GSK

**Ownership Interest:**

- Catena Pharmaceuticals, PTV Ventures, Spindle Top Ventures
- Johnson & Johnson

**Consultant/advisory role:**

- Genentech, Five Prime

**Research funding:**

- Celgene, BMS, Genentech, Merck, Novartis, Amgen, Mirati, GSK, Pfizer, Bayer, Five Prime, Incyte

**Ownership Interest:**

- Tetralogic Pharmaceuticals

**Consultant/advisory role:**

- Celgene, Foundation Medicine

**Honoraria:**

- Celgene, Novartis, Foundation Medicine

**Research funding:**

- Merck, Genentech, Novartis, DNAtrix
After successful completion of this educational activity, participants should be able to:

- Describe the challenges of consenting patients for genomics research, acquiring adequate samples, constructing a consortium to process samples and analyze data, and distributing data for public consumption.
- Summarize major findings from the genomic data reports to date.
- Explain the differences and commonalities of various prognostic models available today.
- Describe the factors in selection of the best prognostic model in clinical practice.
- Discuss recent developments in the treatment of ovarian cancer.
- Describe the opportunities and challenges related to the efficient implementation of PARP inhibitors.
- Describe the nature of AML as a heterogeneous disease based on cytogenetic and molecular findings.
- Cite ways in which cytogenetic and molecular findings impact diagnoses, prognosis, and therapy.
- Identify features of ibrutinib response, toxicity, and relapse in CLL.
- Cite strategies that might be employed to identify and treat ibrutinib refractory CLL.
- Apply results from CD138-selected myeloma FISH panel to treatment of the newly diagnosed multiple myeloma patient.
- Cite the indications for testing bone marrow samples for minimal residual disease and targeted genetic probes in myeloma patients.
- Explain the utility of aberrantly methylated DNA for gastrointestinal cancer screening.
- Describe the process for biomarker development, specifically for pancreatico-biliary cancers.
- Describe the application of Next-Generation Sequencing in identifying therapy opportunities for colorectal cancer patients.
- Explain how trials for colorectal cancer patients may lead to rapid registration of newer, more effective therapies.
- Describe the relative frequency and distribution of primary and secondary kinase mutations in GIST.
- Better delineate key genetic factors and pathways underlying development and progression of prostate cancer.
- Identify new and emerging genetic analyses and processes impacting selection of therapy to better optimize individualized treatment for patients with prostate cancer.
- Cite the role of KIT and PDGFRA genotyping in the management of localized and advanced GIST.
- Discuss the broad diversity of genomic changes within non-small cell lung cancers.
- Incorporate ongoing findings from clinical trials of patients with specific genomic changes into the evaluation and treatment of patients with non-small cell lung cancer.
- Discuss the broad diversity of genomic changes that can be effectively targeted within non-small cell lung cancers.
- Incorporate ongoing findings from clinical trials of patients with specific genomic changes into the evaluation and treatment of patients with non-small cell lung cancer.
- Cite the multiple intrinsic subtypes of high-grade, muscle-invasive bladder cancer.
- Discuss ways in which the intrinsic subtypes of bladder cancer are similar to breast cancer subtypes.
- Determine when to add traztuzumab to chemotherapy in patients with gastric cancer.
- Describe the implications for prognosis and treatment of defective mismatch repair in patients with colorectal cancer.
- Define molecular markers related to aging.
- Discuss the potential role of these markers in patient cancer.
- Describe the types of mutations which may be present in patients presenting with melanoma.
- Prescribe appropriate treatment for patients with identified mutations.
- Describe the advances in molecular classification of gliomas.
- Discuss therapeutic strategies based on molecular profiling of gliomas.
- Describe potential applications for clinical tumor sequencing.
- Explain challenges for precision cancer medicine.
- Explain the “big data” approach to a cure for cancer.
- Describe the importance of data sharing by cancer centers to the search for a cure for cancer.
Every trial, regardless of outcome, can have a benefit to the research community. *Clinical Trial Results* (CTR) from *The Oncologist* promotes the mission of sharing these results to speed discoveries. By providing a platform that allows for rapid publication of important results, this journal section offers a powerful solution for cooperation and transparency while encouraging the publication of results not otherwise reported.

To facilitate the fast-track dissemination of results, CTR uses a menu-driven submission system that guides authors through a number of fields, standardizing the presentation of the trial, its results, and lessons learned. No separate manuscript preparation is necessary. The end-product of this easy-to-use platform is a concise, information-packed report.

**CTR optimizes data by generating:**
- Waterfall plots
- Adverse event and dose-limiting toxicity tables
- Kaplan-Meier curves

**Fully indexed in MEDLINE/PubMed**

**Submit phase I and phase II trial results today.**

[ClinicalTrialResults.TheOncologist.com](http://ClinicalTrialResults.TheOncologist.com)

**Recently Published Results**

- A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
- Phase II Study of Sorafenib and Bortezomib for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma
- Pemetrexed and Gemcitabine Versus Carboplatin and Gemcitabine in Non-Small Cell Lung Cancer: A Randomized Noninferiority Phase II Study in One Center
- Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors
- Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area
The AlphaMed Press Journals App

Instant mobile access to *The Oncologist*


- Full issues are downloadable for convenient offline reading
- Articles, high resolution figures, and tables can be easily emailed to yourself or colleagues
- Push notifications alert you to new issues
- Favorites function lets you bookmark articles for later reference
- Access to educational videos, CME, and other special content available through the Links menu

Download the free AlphaMed Press Journals App today!